The new grant program is funded by Sanofi and Regeneron.

The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023. 

The awards are intended to support dermatologic research projects conducted by junior investigators in the U.S. SID will conduct an independent review of grant applications. Applications must pertain to Type 2 immunity or diseases characterized by Type 2 inflammation, including but not limited to: atopic dermatitis or eczema, chronic urticaria, allergic contact dermatitis, prurigo nodularis, keloids, systemic scleroderma, localized scleroderma (or morphea), hand and foot dermatitis, bullous pemphigoid, and alopecia areata. 

There will be up to four awards of $125,000 each. Recipients will be announced in fall 2023.

“Although improved understanding of Type 2 inflammatory diseases has led to major advances in the care and treatment of our patients with activation of these pathways, much remains to be learned. Unravelling the mechanisms of activation of these pathways in the skin, and the downstream effects, will instigate further discovery and potentially identify novel therapeutic targets not only for skin diseases, but also Type 2 inflammatory diseases that affect other organ systems.” says Dr. Lynn Cornelius, SID President, in a news release. “The SID is grateful to Sanofi and Regeneron for providing this funding as an acknowledgment of their trust in our scientific community to aid in these discovery efforts.”

PHOTO CAPTION: Pictured left to right: Stacey Moore, Physician Resources, LLC; Deb Sierka, PharmD, Sanofi; Stephane Levy, MD, Regeneron Pharmaceuticals, Inc.; Becky Minnillo, PhD, SID; Andrew Korotzer, PhD, Regeneron Pharmaceuticals, Inc.; Lisa Beck, MD, SID